Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposome-CHX-A''-DTPA-213Bi
- Development stage
- Preclinical
- Lead developer
- Johns Hopkins University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**liposome-CHX-A''-DTPA-213Bi** is a preclinical targeted alpha-therapy radiopharmaceutical consisting of the alpha-emitting radionuclide bismuth-213 chelated by CHX-A''-DTPA on an approximately 100-nm liposomal nanoparticle. Following intravenous administration, bismuth-213 decay delivers high-linear-energy-transfer alpha radiation that causes localized, nonselective DNA damage and tumor-cell death. The exact non-antibody-conjugated construct was evaluated in a rat HER2/neu transgenic mouse model of metastatic mammary carcinoma; it improved survival relative to untreated and nonradioactive liposomal controls. The distinct 7.16.4 antibody-conjugated immunoliposome is a related but separate HER2/neu-targeted version and is not the exact drug annotated here. ([publications.jrc.ec.europa.eu](https://publications.jrc.ec.europa.eu/repository/handle/JRC56313))
- Other names
- liposome-CHX-A''-DTPA-(213)Biliposome-CHX-A''-DTPA-213Biliposome-CHX-A″-DTPA-(213)Biliposome-CHX-A″-DTPA-213Bi
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on liposome-CHX-A''-DTPA-213Bi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposome-CHX-A''-DTPA-213Bi.